Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M

Zai Lab Ltd

2024-Q1 EPS reported -$0.05 revenue$87,149,000

Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).
Net loss $53.5M ($0.55 loss per ADS) vs $49.1M in Q1 2023; R&D $54.6M, SG&A $69.2M.
Cash $750.8M at Mar 31, 2024, down from $806.5M at Dec 31, 2023.
Appointed Andrew Zhu as Chief Commercial Officer for Greater China in April 2024.
Regulatory milestones: sBLA submitted for efgartigimod SC in CIDP; potential NMPA approvals for repotrectinib, sulbactam-durlobactam, efgartigimod SC in gMG in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zai Lab Ltd reported the first quarter of 2024 results: revenue $87.1 million, net income $53.5 million, EPS loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55).

Period: the first quarter of 2024
Revenue: $87.1 million
Net income: $53.5 million
EPS: loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55)
Result: reported results

Exact text from the filing

by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) sales of $13.2 million

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-24-021674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.